All In Biotech

Free tool

FAERS Monitor: Duvyzat

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217865 or its brand name (Duvyzat, Givinostat Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

635

Serious

172

27% of reports

Hospitalization

70

Death reported

17

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • platelet count decreased132
  • diarrhoea85
  • blood triglycerides increased60
  • abdominal discomfort46
  • vomiting45
  • nausea44
  • weight increased40
  • thrombocytopenia39
  • product dose omission issue38
  • off label use27
  • pyrexia27
  • abdominal pain upper25
  • fatigue21
  • abdominal pain20
  • fall20

Reports by year received

View as table
YearReports
20212
202449
2025374
2026210

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,524 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood triglycerides increasedSignal60112.988.76,525
platelet count decreasedSignal13241.135.35,140
thrombocytopeniaSignal3911.68.5367
abdominal discomfortSignal469.16.9325
weight increasedSignal405.94.4160
diarrhoeaSignal854.43.6224
product dose omission issueSignal384.33.194
abdominal pain upperSignal254.02.754
vomitingSignal453.22.466
abdominal painSignal202.81.922
pyrexiaSignal272.61.825
fall202.01.39
nausea441.81.417
off label use271.00.70
fatigue210.90.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.